Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy - PubMed (original) (raw)
Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy
Peter B Illei et al. Appl Immunohistochem Mol Morphol. 2016 Apr.
Abstract
The identification of new therapeutic targets is of profound importance if we are to improve outcomes in gastroesophageal cancer. This study assessed the rate of mesothelin expression in tumors of western patients with upper gastrointestinal tract carcinomas. In addition, the AGS gastric cancer cell line was tested for sensitivity to SS1(dsFv)PE38, a mesothelin-targeting immunotoxin. Previously constructed tissue microarrays containing samples from 127 patients with gastroesophageal adenocarcinomas were examined by immunohistochemistry (IHC) for mesothelin expression. Labeling for HER2-neu, E-cadherin, and c-met were also assessed. Tumors were considered positive for mesothelin if at least moderate cytoplasmic/membranous or luminal staining was present in minimum 10% of the neoplastic cells. The AGS gastric cancer cell line was assessed for surface mesothelin expression by flow cytometry and the viability of cells treated with SS1P was measured. Gastroesophageal cancers were mesothelin positive in 64 of 127 tumors [50.4%; 95% confidence interval (CI), 41.4%-59.4%], whereas only 9 carcinomas (7.1%; 95% CI, 3.3%-13.0%) were HER2-neu IHC 3+ positive and 8 (6.6%; 95% CI, 2.9%-12.5%) were c-met positive. Mesothelin expression increased from stage I to stage IV tumors (37.5% to 56.3%, respectively, P=0.10). The AGS gastric cancer cell line was sensitive to the immunotoxin with an EC50 value in the low picomolar range (0.4 ng/mL). A gastric cancer cell line derived from a western patient was exquisitely sensitive to the mesothelin-targeted immunotoxin SS1P. Clinical trials involving novel mesothelin targeted immunotherapeutics in gastroesophageal cancer are currently in development.
Figures
Figure 1
Representative images of immunohistochemistry for mesothelin, E-cadherin, Her2/Neu and c-met.
Figure 2
FACS analysis of mesothelin surface expression of AGS cells. Live cells were labeled with anti-mesothelin antibody and then antibody was detected with PE-conjugated secondary antibody. A) Representative histogram of PE detection in greater than 20,000 AGS cells (shaded curve) compared to control (unfilled curve). B) WST-8 cell viability assay of SS1P treated AGS cells. 100% viability was normalized to measurement for untreated cells and 0% viability to cells treated with 10 mcg/mL cyclohexamide which produces complete cell death. A representative cytotoxicity curves is shown. Each point represents the average of triplicate measurements. The dotted horizontal line marks 50% cell killing. The vertical arrow indicates the IC50 for the run. The average IC50 after 8 experiments was 0.4 ng/mL.
Similar articles
- Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I. Hassan R, et al. Clin Cancer Res. 2002 Nov;8(11):3520-6. Clin Cancer Res. 2002. PMID: 12429643 - Mesothelin expression in human lung cancer.
Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. Ho M, et al. Clin Cancer Res. 2007 Mar 1;13(5):1571-5. doi: 10.1158/1078-0432.CCR-06-2161. Clin Cancer Res. 2007. PMID: 17332303 - Mesothelin: a new target for immunotherapy.
Hassan R, Bera T, Pastan I. Hassan R, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. doi: 10.1158/1078-0432.CCR-03-0801. Clin Cancer Res. 2004. PMID: 15217923 Review. - Discovery of mesothelin and exploiting it as a target for immunotherapy.
Pastan I, Hassan R. Pastan I, et al. Cancer Res. 2014 Jun 1;74(11):2907-12. doi: 10.1158/0008-5472.CAN-14-0337. Epub 2014 May 13. Cancer Res. 2014. PMID: 24824231 Free PMC article. Review.
Cited by
- Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TC2N.
Yang Z, Zhang H, Xia X, Zhang J. Yang Z, et al. Eur J Microbiol Immunol (Bp). 2024 Feb 15;14(1):59-65. doi: 10.1556/1886.2024.00002. Print 2024 Feb 23. Eur J Microbiol Immunol (Bp). 2024. PMID: 38358441 Free PMC article. - Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma.
Feng F, Zhang H, Zhang Y, Wang H. Feng F, et al. Transl Cancer Res. 2020 Dec;9(12):7479-7485. doi: 10.21037/tcr-19-2027. Transl Cancer Res. 2020. PMID: 35117348 Free PMC article. - In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab.
Roy J, Jagoda EM, Basuli F, Vasalatiy O, Phelps TE, Wong K, Ton AT, Hagemann UB, Cuthbertson AS, Cole PE, Hassan R, Choyke PL, Lin FI. Roy J, et al. Cancer Biother Radiopharm. 2021 May;36(4):316-325. doi: 10.1089/cbr.2020.4492. Cancer Biother Radiopharm. 2021. PMID: 34014767 Free PMC article. - Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors.
Weidemann S, Gagelmann P, Gorbokon N, Lennartz M, Menz A, Luebke AM, Kluth M, Hube-Magg C, Blessin NC, Fraune C, Möller K, Bernreuther C, Lebok P, Clauditz TS, Jacobsen F, Izbicki JR, Jansen K, Sauter G, Uhlig R, Wilczak W, Steurer S, Minner S, Burandt E, Krech RH, Dum D, Krech T, Marx AH, Simon R. Weidemann S, et al. Biomedicines. 2021 Apr 7;9(4):397. doi: 10.3390/biomedicines9040397. Biomedicines. 2021. PMID: 33917081 Free PMC article. - Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, Niederfellner G, Méresse Naegelen V, Pastan I. Hassan R, et al. Cancer. 2020 Nov 15;126(22):4936-4947. doi: 10.1002/cncr.33145. Epub 2020 Sep 1. Cancer. 2020. PMID: 32870522 Free PMC article. Clinical Trial.
References
- Hassan RSE, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman R, Steinberg S, Hollevoet K, Pastan I. Phase I Study of the Anti-Mesothelin Immunotoxin SS1P in Combination with Pemetrexed and Cisplatin for Front-Line Therapy of Pleural Mesothelioma and Correlation of Tumor Response with Serum Mesothelin, MPF and CA-125. Cancer. 2014 In Press. - PMC - PubMed
- Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. - PubMed
- Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–39. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous